Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axogen, Inc. filings document a Nasdaq-listed operating company focused on peripheral nerve repair technologies and related surgical products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor presentations, FDA-related disclosures for Avance® (acellular nerve allograft-arwx), and material agreements tied to common stock financing and shelf registration activity.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and pay-versus-performance disclosures. The filing record also identifies Axogen’s common stock structure and corporate governance framework, while event reports record officer compensation arrangements, regulatory language for Avance, and other formal updates to the company’s public disclosure record.
Axogen, Inc. director stock transactions: On 12/16/2025, a director of Axogen, Inc. exercised employee stock options to acquire 18,248 shares of common stock at $7.04 per share and 21,825 shares at $6.95 per share. These exercises increased the director’s direct holdings to 46,653 shares.
On the same date, the director sold 18,248 shares and 21,825 shares at a weighted average sale price of $29.547 per share, and an additional 6,580 shares at $29.55 per share. After these transactions, the director held 0 shares of common stock directly and 43,651 employee stock options, which are exercisable for Axogen common stock.
Axogen, Inc. reported an equity transaction by its Chief Financial Officer. On 12/15/2025, the CFO exercised an employee stock option to acquire 14,812 shares of Axogen common stock at an exercise price of $8.27 per share. On the same date, the CFO sold 14,812 shares of common stock at a weighted average sale price of $29.8605 per share, leaving 31,376 shares of common stock beneficially owned directly after the transactions.
The derivative position tied to this option was reduced to zero following the exercise. The option related to 14,812 underlying shares of Axogen common stock and was scheduled to be fully vested by March 16, 2027 under a vesting schedule where 50% vested on March 16, 2025 and an additional 12.5% vested every six months thereafter.
Axogen, Inc. Chief Executive Officer Michael Dale reported selling 25,000 shares of the company’s common stock on 12/10/2025 at $30 per share. After this sale, he directly beneficially owns 63,537 shares of Axogen common stock.
Axogen, Inc. executive vice president and general counsel Marc Began reported a sale of company stock. On 12/11/2025, he sold 13,222 shares of Axogen common stock at $30 per share. After this transaction, he directly beneficially owns 18,285 shares of Axogen common stock.
Axogen executive Marc Began, EVP & General Counsel, acquired 22,500 shares of Axogen common stock on 12/04/2025 at a reported price of $0 per share. According to the explanation, these shares were issued upon the attainment of certain performance criteria, indicating a performance-based equity award rather than an open-market purchase. Following this transaction, Began beneficially owns 40,785 shares of Axogen common stock.
Axogen, Inc. reported that its Compensation Committee approved higher pay and updated restrictive covenants for Chief Financial Officer Lindsey Hartley. Effective January 1, 2026, her annual base salary will increase by 7%, and her target bonus opportunity under the company’s annual incentive program will rise from 50% to 60% of her annual base salary. The company and Ms. Hartley also entered into an Amended and Restated Confidentiality, Intellectual Property, Non-Competition and Non-Solicitation Agreement, effective December 5, 2025, which includes a two-year post-employment non-competition covenant, while her other compensatory arrangements remain unchanged.
Axogen, Inc. announced that the U.S. Food and Drug Administration has approved its Biologics License Application for Avance® (acellular nerve allograft-arwx), a nerve repair product. Some indications, including sensory nerve discontinuities greater than 25 mm and mixed and motor nerve discontinuities, were cleared under the FDA’s Accelerated Approval pathway based on improvements in static two-point discrimination in smaller sensory nerve gaps. Continued approval for these uses depends on confirmatory studies that verify and describe clinical benefit. The company expects the licensed Avance product to be commercially available in early second quarter 2026, while Avance remains available under the current tissue framework until then.
Axogen (AXGN) insider activity: Director William Burke reported option exercises and open‑market sales executed under a Rule 10b5‑1(c) plan adopted March 14, 2025. On 11/10/2025, he exercised stock options at $8.14 to acquire 19,227 shares, then sold 19,227 shares at a weighted average price of $24.01, with trades ranging from $24.00 to $24.10. On 11/11/2025, he exercised options at $8.14 for 3,591 shares and sold 3,591 shares at a weighted average price of $24.018, with trades from $24.00 to $24.13.
Following these transactions, he directly owned 100 shares. The exercised options carried a $8.14 exercise price and an expiration of July 11, 2032, from a grant that vested in three equal annual installments on the annual anniversary of the grant date, July 11, 2022.
Axogen (AXGN) Form 4: Director William Burke reported option exercises and matched open‑market sales executed under a Rule 10b5‑1(c) trading plan adopted March 14, 2025. On 11/05/2025, he exercised 11,431 stock options at $8.14 and sold 11,431 shares at a weighted average price of $24.048, with trades ranging from $24.00 to $24.25. On 11/06/2025, he exercised 5,347 options at $8.14 and sold 5,347 shares at a weighted average of $24.008, with trades from $24.00 to $24.06.
Following these transactions, he held 100 shares of common stock directly. The underlying options are from a grant that vested in three equal annual installments on the anniversary of the July 11, 2022 grant date and carry an expiration of 07/11/2032. The filing shows 22,818 derivative securities beneficially owned after the 11/06 activity.
Axogen, Inc. (AXGN): Director Form 4 activity
Director reported option exercises and same‑day open‑market sales under a Rule 10b5‑1(c) trading plan adopted March 14, 2025. On 10/29/2025, options for 20,436 shares were exercised at $6.30 and sold at a weighted average $19.1542 (shares sold at prices from $19.00 to $19.50). Also on 10/29/2025, options for 19,799 shares were exercised at $8.14 and sold at $22. On 10/30/2025, options for 18,248 shares were exercised at $7.04 and sold at $23.
Following these transactions, direct beneficial ownership of common stock was 100 shares. The $6.30 and $7.04 option grants show 0 remaining after exercise, while the $8.14 grant shows 39,596 derivative securities beneficially owned following the reported transactions.